IP : Tissue Regenix Group plc - Notice of results

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that its interim results for the six months ended 30 June 2021 will be announced on Wednesday, 8 September 2021.

Investor presentation

Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm (BST) on Wednesday 8 September 2021. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor

Investors who already follow Tissue Regenix on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-eventvia your IMC dashboard or in real time during the presentation, via the 'Ask a Question' function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

For more information:

Tissue Regenix Group plc	www.tissueregenix.com Via Walbrook PR
David Cocke, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: [phone]
Ben Maddison / Alex Price
Walbrook PR Ltd	Tel: [phone] [e-mail]
Alice Woodings / Lianne Cawthorne

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.